Inclusion Criteria:  Histopathologically proven cases of locally advanced head and neck cancers (LAHNC), TNM stages III and IV and locally advanced cancer cervix (LACC), FIGO stages IIB - IVA, locally advanced (primarily inoperable T3 and T4 stages) and recurrent breast cancers, cancer oesophagus (TNM stages IIA and IVA), anorectal cancers (TNM stages IIA to IIIC) Following work up, patients should have no metastatic disease (M0) Age > 18 years Karnofsky performance status (KPS) ≥ 80 Written informed consent and agree to comply with the protocol Adequate kidney and liver functions as assessed on biochemical investigations Absence of psychological, familial, sociological or geographical condition that could potentially hamper compliance with the study protocol and follow-up schedule  Exclusion Criteria:  Prior radiotherapy to the site of treatment No prior or concurrent malignancies other than surgically treated squamous cell or basal cell carcinoma of the skin which are not in the area of the present malignancy Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator would preclude the patient from meeting the study requirements. Patients having metal implants, pacemakers or clustered markers. Connective disease disorders that contraindicate radiotherapy, e.g., Scleroderma Any known contraindication or hypersensitivity to the chemotherapeutic agents Pregnancy, lactation period or lack of reliable contraception Any other disease or therapy, which, according to the investigator, present a risk to the patient or which are not compatible with the aims of the clinical trial Indications that the person concerned will possibly not keep to the clinical trial plan because of unwillingness to cooperate or difficulties in keeping the check-up appointments Breast feeding female patients